Eli Lilly's Foundayo (orforglipron) has been granted expedited approval by the U.S. Food and Drug Administration (FDA), making it the second daily oral medication for obesity and related conditions. This GLP-1 medication mimics a natural hormone that regulates appetite and fullness, similar to injectable treatments. Shipments of Foundayo will commence on Monday, with insured patients paying between $149 and $349 per month depending on the dosage. In a clinical trial involving over 3,000 adults with obesity, those taking the highest dose of orforglipron lost an average of 25 pounds, or 11.2% of their body weight, over more than 16 months. This is significantly higher than the 2.1% weight loss seen in the placebo group. While both Foundayo and Novo Nordisk's oral Wegovy have shown efficacy, they resulted in less weight loss compared to injectable options like Lilly's Zepbound and Novo Nordisk's Wegovy. Users of orforglipron also experienced improvements in waist circumference, blood pressure, and cholesterol levels. However, gastrointestinal side effects caused 5% to 10% of participants to discontinue treatment, compared to nearly 3% in the placebo group. Foundayo will be part of a Trump administration initiative aimed at reducing prices for GLP-1 drugs, addressing affordability issues faced by many users of injectable medications.